Josh is a Special Partner on NEA's healthcare team and has worked closely with NEA since his time as an EIR back in 1995, stepping up as a General Partner to lead our medtech/healthtech practice from 2015 to 2021. In addition to his continuing role at NEA, Josh serves on the faculty of the Stanford University Medical and Engineering Schools as a Professor of Medicine and Bioengineering and is Director and Co-Founder of The Stanford Byers Center for Biodesign. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 9 companies over the past 25 years. Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009, EndoMatrix, acquired by C.R. Bard in 1997, TransVascular, acquired by Medtronic in 2003, Nuelle, acquired by AyTu Biosciences in 2014, and Neotract acquired by Teleflex in 2017. On-going ExploraMed/NEA ventures include Moximed, Willow Innovations, Revelle Aesthetics, and ExploraMed V. Josh currently serves on the boards of Eargo (NASDAQ: EAR), Allay Therapeutics, Lungpacer, Revelle Aesthetics, Magenta Medical, DOTS Technology Corp., ExploraMed, Intrinsic Therapeutics, Moximed, SetPoint Medical, Willow and Coravin. Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, aesthetics, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor's degree in Mechanical Engineering from MIT, and is a Fellow of the American Institute of Biomedical Engineering and a member of the National Academy of Engineering.